Expanded Access to Retatrutide for Severe Obesity Patients Announced | Retatrutide News

Retatrutide, a triple receptor agonist, is now available for expanded access to adults with severe obesity. This option is for those who cannot join ong...
Clinical Trials · October 28, 2026